» Articles » PMID: 24740362

Maternal Plasma RNA Sequencing for Genome-wide Transcriptomic Profiling and Identification of Pregnancy-associated Transcripts

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2014 Apr 18
PMID 24740362
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Analysis of circulating RNA in the plasma of pregnant women has the potential to serve as a powerful tool for noninvasive prenatal testing and research. However, detection of circulating RNA in the plasma in an unbiased and high-throughput manner has been technically challenging. Therefore, only a limited number of circulating RNA species in maternal plasma have been validated as pregnancy- and placenta-specific biomarkers.

Methods: We explored the use of massively parallel sequencing for plasma transcriptome profiling in first-, second-, and third-trimester pregnant women. Genotyping was performed for amniotic fluid, placental tissues, and maternal blood cells, with exome-enriched sequencing.

Results: In the early pregnancy group comprising 1 first- and 1 second-trimester pregnancy cases, the fetal contribution to the RNA pool in maternal plasma was 3.70%. The relative proportion of fetal contribution was increased to 11.28% in the late pregnancy group comprising 2 third-trimester pregnancy cases. The placental biallelic expression pattern of PAPPA (pregnancy-associated plasma protein A, pappalysin 1), a known pregnancy-specific gene, and the monoallelic expression pattern of H19 [H19, imprinted maternally expressed transcript (non-protein coding)], an imprinted maternally expressed gene, were also detected in the maternal plasma. Furthermore, by direct examination of the maternal plasma transcriptomic profiles before and after delivery, we identified a panel of pregnancy-associated genes.

Conclusions: Plasma RNA sequencing provides a holistic view of the maternal plasma transcriptomic repertoire. This technology is potentially valuable for using circulating plasma nucleic acids for prenatal testing and research.

Citing Articles

Advancing diagnosis and early risk assessment of preeclampsia through noninvasive cell-free DNA methylation profiling.

Baetens M, Van Gaever B, Deblaere S, De Koker A, Meuris L, Callewaert N Clin Epigenetics. 2024; 16(1):182.

PMID: 39695764 PMC: 11656954. DOI: 10.1186/s13148-024-01798-5.


Deciphering maternal-fetal cross-talk in the human placenta during parturition using single-cell RNA sequencing.

Garcia-Flores V, Romero R, Tarca A, Peyvandipour A, Xu Y, Galaz J Sci Transl Med. 2024; 16(729):eadh8335.

PMID: 38198568 PMC: 11238316. DOI: 10.1126/scitranslmed.adh8335.


Circulating Non-coding RNAs and Exosomes: Liquid Biopsies for Monitoring Preeclampsia.

Li N, Gu Y, Tang J, Li Y, Chen D, Xu Z Methods Mol Biol. 2023; 2695:263-277.

PMID: 37450125 DOI: 10.1007/978-1-0716-3346-5_18.


Identification of novel cell-free RNAs in maternal plasma as preterm biomarkers in combination with placental RNA profiles.

Jin H, Zhang Y, Fan Z, Wang X, Rui C, Xing S J Transl Med. 2023; 21(1):256.

PMID: 37046301 PMC: 10100253. DOI: 10.1186/s12967-023-04083-w.


Reappraisal of evolving methods in non-invasive prenatal screening: Discovery, biology and clinical utility.

Rather R, Saha S Heliyon. 2023; 9(3):e13923.

PMID: 36879971 PMC: 9984859. DOI: 10.1016/j.heliyon.2023.e13923.